Esperion Therapeutics (NASDAQ:ESPR - Get Free Report)'s stock had its "buy" rating reaffirmed by research analysts at HC Wainwright in a note issued to investors on Wednesday,Benzinga reports. They currently have a $16.00 price objective on the biopharmaceutical company's stock.
Several other research firms have also recently issued reports on ESPR. Needham & Company LLC cut their target price on Esperion Therapeutics from $8.00 to $6.00 and set a "buy" rating for the company in a research report on Tuesday, August 13th. StockNews.com cut Esperion Therapeutics from a "buy" rating to a "hold" rating in a research report on Friday, November 15th.
View Our Latest Stock Report on ESPR
Esperion Therapeutics Price Performance
Shares of ESPR opened at $2.57 on Wednesday. The business has a 50-day simple moving average of $2.06 and a two-hundred day simple moving average of $2.16. The stock has a market cap of $506.39 million, a price-to-earnings ratio of -4.02 and a beta of 0.96. Esperion Therapeutics has a 52 week low of $1.16 and a 52 week high of $3.40.
Institutional Investors Weigh In On Esperion Therapeutics
Institutional investors have recently modified their holdings of the stock. BOKF NA bought a new stake in shares of Esperion Therapeutics in the 2nd quarter valued at approximately $26,000. Traphagen Investment Advisors LLC bought a new stake in shares of Esperion Therapeutics during the 3rd quarter worth approximately $27,000. Xponance Inc. bought a new stake in shares of Esperion Therapeutics during the 2nd quarter worth approximately $28,000. National Bank of Canada FI lifted its stake in shares of Esperion Therapeutics by 115.9% during the 2nd quarter. National Bank of Canada FI now owns 19,050 shares of the biopharmaceutical company's stock worth $44,000 after acquiring an additional 10,225 shares during the last quarter. Finally, Sivia Capital Partners LLC bought a new stake in shares of Esperion Therapeutics during the 2nd quarter worth approximately $44,000. 47.39% of the stock is owned by institutional investors.
Esperion Therapeutics Company Profile
(
Get Free Report)
Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Esperion Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Esperion Therapeutics wasn't on the list.
While Esperion Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
